Literature DB >> 26766582

Molecular modelling, synthesis and biological evaluation of peptide inhibitors as anti-angiogenic agent targeting neuropilin-1 for anticancer application.

Ezatul E Kamarulzaman1,2, Régis Vanderesse2, Amirah M Gazzali2, Muriel Barberi-Heyob3, Cédric Boura3, Céline Frochot4, Omar Shawkataly5, André Aubry2, Habibah A Wahab1,6.   

Abstract

Vascular endothelial growth factor (VEGF) and its co-receptor neuropilin-1 (NRP-1) are important targets of many pro-angiogenic factors. In this study, nine peptides were synthesized and evaluated for their molecular interaction with NRP-1 and compared to our previous peptide ATWLPPR. Docking study showed that the investigated peptides shared the same binding region as shown by tuftsin known to bind selectively to NRP-1. Four pentapeptides (DKPPR, DKPRR, TKPPR and TKPRR) and a hexapeptide CDKPRR demonstrated good inhibitory activity against NRP-1. In contrast, peptides having arginine residue at sites other than the C-terminus exhibited low activity towards NRP-1 and this is confirmed by their inability to displace the VEGF165 binding to NRP-1. Docking study also revealed that replacement of carboxyl to amide group at the C-terminal arginine of the peptide did not affect significantly the binding interaction to NRP-1. However, the molecular affinity study showed that these peptides have marked reduction in the activity against NRP-1. Pentapeptides having C-terminal arginine showed strong interaction and good inhibitory activity with NRP thus may be a good template for anti-angiogenic targeting agent.

Entities:  

Keywords:  ELISA; VEGFR; angiogenesis; docking study; in vitro binding; molecular modelling; neuropilin-1; synthetic peptides

Mesh:

Substances:

Year:  2016        PMID: 26766582     DOI: 10.1080/07391102.2015.1131196

Source DB:  PubMed          Journal:  J Biomol Struct Dyn        ISSN: 0739-1102


  6 in total

1.  Multiscale Selectivity and in vivo Biodistribution of NRP-1-Targeted Theranostic AGuIX Nanoparticles for PDT of Glioblastoma.

Authors:  Mickaël Gries; Noémie Thomas; Joël Daouk; Paul Rocchi; Laurence Choulier; Justine Jubréaux; Julien Pierson; Aurélie Reinhard; Valérie Jouan-Hureaux; Alicia Chateau; Samir Acherar; Céline Frochot; François Lux; Olivier Tillement; Muriel Barberi-Heyob
Journal:  Int J Nanomedicine       Date:  2020-11-09

2.  Enhanced glioma-targeting and stability of LGICP peptide coupled with stabilized peptide DA7R.

Authors:  Mingfei Zhang; Weiyue Lu
Journal:  Acta Pharm Sin B       Date:  2018-01-03       Impact factor: 11.413

3.  New Targeted Gold Nanorods for the Treatment of Glioblastoma by Photodynamic Therapy.

Authors:  Zahraa Youssef; Nurlykyz Yesmurzayeva; Ludivine Larue; Valérie Jouan-Hureaux; Ludovic Colombeau; Philippe Arnoux; Samir Acherar; Régis Vanderesse; Céline Frochot
Journal:  J Clin Med       Date:  2019-12-13       Impact factor: 4.241

4.  Preliminary Study of New Gallium-68 Radiolabeled Peptide Targeting NRP-1 to Detect Brain Metastases by Positron Emission Tomography.

Authors:  Albert Moussaron; Valérie Jouan-Hureaux; Charlotte Collet; Julien Pierson; Noémie Thomas; Laurence Choulier; Nicolas Veran; Matthieu Doyen; Philippe Arnoux; Fatiha Maskali; Dominique Dumas; Samir Acherar; Muriel Barberi-Heyob; Céline Frochot
Journal:  Molecules       Date:  2021-11-30       Impact factor: 4.411

5.  Ultrasmall AGuIX theranostic nanoparticles for vascular-targeted interstitial photodynamic therapy of glioblastoma.

Authors:  Eloïse Thomas; Ludovic Colombeau; Mickaël Gries; Thibaut Peterlini; Clélia Mathieu; Noémie Thomas; Cédric Boura; Céline Frochot; Régis Vanderesse; François Lux; Muriel Barberi-Heyob; Olivier Tillement
Journal:  Int J Nanomedicine       Date:  2017-09-26

6.  Does Cysteine Rule (CysR) Complete the CendR Principle? Increase in Affinity of Peptide Ligands for NRP-1 Through the Presence of N-Terminal Cysteine.

Authors:  Anna K Puszko; Piotr Sosnowski; Françoise Raynaud; Olivier Hermine; Gérard Hopfgartner; Yves Lepelletier; Aleksandra Misicka
Journal:  Biomolecules       Date:  2020-03-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.